Lancet (London, England) · 2008
Spinal muscular atrophy.
СтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lunn Mitchell R, Wang Ching H
Аннотация
Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness. It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation. Although no medical treatment is available, investigations have elucidated possible mechanisms underlying the molecular pathogenesis of the disease. Treatment strategies have been developed to use the unique genomic structure of the SMN1 gene region. Several candidate treatment agents have been identified and are in various stages of development. These and other advances in medical technology have changed the standard of care for patients with spinal muscular atrophy. In this Seminar, we provide a comprehensive review that integrates clinical manifestations, molecular pathogenesis, diagnostic strategy, therapeutic development, and evidence from clinical trials.
Предметные рубрики MeSH
Action PotentialsAminesCyclic AMP Response Element-Binding ProteinCyclohexanecarboxylic AcidsElectromyographyGabapentinGene LibraryHumansMolecular BiologyNerve Tissue ProteinsPhenylbutyratesRNA-Binding ProteinsRandomized Controlled Trials as TopicSMN Complex ProteinsSeverity of Illness IndexSpinal Muscular Atrophies of ChildhoodSurvival of Motor Neuron 1 Proteingamma-Aminobutyric Acid